Gossypin 是一种从 Hibiscus vitifolius 中发现的有口服活性的黄酮,具有抗氧化、抗炎、抗癌、抗衰老、抗糖尿病和保护肝脏的活性,可抑制 NF-κB 及其调节基因表达,抑制 AURKA 和 RSK2,抑制细胞侵袭并诱导凋亡 (apoptosis),可用于胃癌的研究。
产品编号: MS-J16809 纯度: 98.29% CAS No.: 652-78-8 分子式: C21H20O13 分子量: 480.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Gossypin 是一种从 Hibiscus vitifolius 中发现的有口服活性的黄酮,具有抗氧化、抗炎、抗癌、抗衰老、抗糖尿病和保护肝脏的活性,可抑制 NF-κB 及其调节基因表达,抑制 AURKA 和 RSK2,抑制细胞侵袭并诱导凋亡 (apoptosis),可用于胃癌的研究。

生物实验数据

生物活性 Gossypin is an orally active flavonoid discovered in Hibiscus vitifolius that exhibits antioxidant, anti-inflammatory, anticancer, anti-aging, antidiabetic, and hepatoprotective activities, inhibits NF-κB and NF-κB-regulated gene expression, inhibits AURKA and RSK2, suppresses cell invasion and induces apoptosis, and can be used for the study of gastric cancer.
IC50 & Target

IC50: NF-κB

体外研究
(In Vitro)

Gossypin (10-100 μM,0.5-8 小时,然后用 TNF 处理 30 分钟) 可抑制 KBM-5 细胞中 NF-κB 活化,导致凋亡增加,抑制细胞的侵袭。
Gossypin (50 μM, 3-5 days) 在 RAW 264.7 和C57BL/6J 小鼠原代骨髓细胞中抑制 RANKL 诱导的破骨细胞生成。
Gossypin (10-60 μM,72 小时或 2 周) 抑制胃癌细胞生长。
Gossypin (20-40 μM,48 小时) 显著抑制胃癌细胞迁移。
Gossypin( 5-60 μM,1-24 小时) 抑制 JB6 细胞和 HGC27 细胞中的 AURKA 和 RSK2。
Gossypin (40 μM,48 小时) 诱导 G2/M 期细胞周期停滞。
Gossypin (40-60 μM,72 小时) 增加胃癌细胞凋亡。

Cell Cycle Analysis

Cell Line: HGC27 human gastric cancer cells, AGS human gastric cancer cells
Concentration: 20, 40, 60 μM (72 h), or 10, 20, 40 μM (2 weeks)
Incubation Time: (40 μM) 48 h or 72 h or 2 weeks
Result: Reduced S phase and induced G2 phase cell cycle arrest.
Reduced the expression of cyclin A2, cyclin B1, and phosphorylated CDC2 proteins.
Growth of gastric cancer cells was significantly inhibited in a dose dependent manner.

Apoptosis Analysis

Cell Line: HGC27 human gastric cancer cells
Concentration: 40, 60 μM
Incubation Time: 72 h
Result: Increased the number of suspended cells (dead), decreased the number of adherent cells (live).
Early and late apoptosis cells were strongly increased compared to control cells.
Increased expression of pro-apoptotic marker proteins (cleaved caspase 3, 7 and 9, cleaved PARP and cytochrome c), decreased expression of anti-apoptotic marker protein (BcL-xL).

Cell Migration Assay

Cell Line: HGC27 human gastric cancer cells, AGS human gastric cancer cells
Concentration: 20, 40 μM
Incubation Time: 48 h
Result: Significantly suppressed migration.

Western Blot Analysis

Cell Line: KBM-5 (chronic myeloid leukemia)
Concentration: 0.5, 1, 2, 4, 8 h, and then treated with TNF for 30 minutes; or 2 h then treated with TNF for 16 h; or Preincubated for 30 minutes before add TNF, H2O2, PMA, LPS, IL-1β, OA, CSC
Incubation Time: 2.5 h (2 hours alone and then treated with TNF for 30 minutes)
Result: Blocked NF-κB activation induced by tumor necrosis factor (TNF), H2O2, Phorbol myristate acetate (PMA), Lipopolysaccharides (LPS) (MS-X54539), interleukin-1β (IL-1β), okadaic acid (OA), cigarette smoke condensate (CSC).
Suppressed TNF-induced NF-κB in a dose-dependent manner.
Suppressed TNF-induced NF-κB in a time-dependent manner.
Enhanced TNF-induced apoptosis.

Western Blot Analysis

Cell Line: RAW 264.7 cells, Mouse (C57BL/6J) primary bone marrow cells
Concentration: 50 μM
Incubation Time: 5 days (RAW 264.7 cells) or 3 days (primary bone marrow cells)
Result: Decreased RANKL-induced osteoclast differentiation in RAW 264.7 cells.
50 μM concentration was sufficient to reduce osteoclastogenesis by more than 65% in RAW 264.7 cells.
Under these conditions, RAW 264.7cells remained fully viable.
Substantially decreased RANKL-induced osteoclast differentiation in primary bone marrow cells.
体内研究
(In Vivo)

Gossypin (10-20 mg/kg;口服;持续30天) 通过改变氧化应激、炎症反应和肠道微生物群,减轻 Isoprenaline (ISO) (MS-N74570) 诱导的大鼠缺血/再灌注 (I/R)。

Animal Model: Sprague Dawley (SD) rats (200-225 g; male; 8-10 weeks)
Dosage: 10, 20 mg/kg
Administration: Oral gavage (p.o.); 30 days
Result: Reduced the infarct size induced by Isoprenaline (ISO) (MS-N74570).
Showed the boosted level of LVESP, SW, ESPVR, DP, EDPVR and suppressed level of LVEDP.
Increased the bodyweight and suppressed the heart weight and heart/body weight ratio.
Suppressed the level of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and increased the level of high-density lipoprotein (HDL).
Suppressed the level of nitric oxide synthase (iNOS) and nitric oxide (NO).
Decreased the level of MMP-2 and MMP-9.
Suppressed the level of inflammatory cytokines (TNF-α, IL-1β, IL-6) and decreased the level of NF-κB in the serum and heart tissue.
Suppressed the apoptosis of muscle fibres with edema and necrosis.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 480.38
分子式 C21H20O13
CAS No. 652-78-8

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 200 mg/mL (416.34 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0817 mL10.4084 mL20.8169 mL52.0421 mL
5 mM0.4163 mL2.0817 mL4.1634 mL10.4084 mL
10 mM0.2082 mL1.0408 mL2.0817 mL5.2042 mL
15 mM0.1388 mL0.6939 mL1.3878 mL3.4695 mL
20 mM0.1041 mL0.5204 mL1.0408 mL2.6021 mL
25 mM0.0833 mL0.4163 mL0.8327 mL2.0817 mL
30 mM0.0694 mL0.3469 mL0.6939 mL1.7347 mL
40 mM0.0520 mL0.2602 mL0.5204 mL1.3011 mL
50 mM0.0416 mL0.2082 mL0.4163 mL1.0408 mL
60 mM0.0347 mL0.1735 mL0.3469 mL0.8674 mL
80 mM0.0260 mL0.1301 mL0.2602 mL0.6505 mL
100 mM0.0208 mL0.1041 mL0.2082 mL0.5204 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Gossypin 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础